Compare $CVM vs $QNCX | Chartloom

Compare

$CVM vs $QNCX

CEL-SCI Corp · Quince Therapeutics Inc

CVM

CEL-SCI Corp

QNCX

Quince Therapeutics Inc

Compare $CVM vs $QNCX

Comparing CEL-SCI Corp and Quince Therapeutics Inc

CVMCEL-SCI Corp

QNCXQuince Therapeutics Inc

CVMCEL-SCI Corp

Market cap

$34M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-62.3%

52W performance

-80.7%

FCF yield

-49.4%

QNCXQuince Therapeutics Inc

Market cap

$31M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-94.7%

52W performance

-91.7%

FCF yield

-151.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CVM

QNCX

Detailed metrics comparison

CVM

CEL-SCI Corp

QNCX

Quince Therapeutics Inc

Market Cap

CVM$34M

QNCX$31M

Enterprise Value

CVM$34M

QNCX$-85M

Price

CVM$1.94

QNCX$31.73

P/E Ratio

CVMN/A

QNCXN/A

P/S Ratio

CVM72.73x

QNCX0.00x

EV/Sales

CVM72.27x

QNCX0.00x

EV/EBITDA

CVM0.00x

QNCX0.00x

P/B Ratio

CVM3.71x

QNCX0.27x

P/FCF Ratio

CVMN/A

QNCXN/A

EV/FCF

CVM-2.01x

QNCX1.81x

PEG Ratio

CVMN/A

QNCXN/A

Forward P/E (NTM)

CVMN/A

QNCXN/A

Forward P/S (NTM)

CVMN/A

QNCXN/A

Revenue (TTM)

CVM$0

QNCX$0

Revenue Growth (YoY)

CVMN/A

QNCXN/A

Forward Rev Growth

CVM0.0%

QNCX114.8%

Gross Margin (TTM)

CVM0.0%

QNCX0.0%

Operating Margin (TTM)

CVM0.0%

QNCX0.0%

EBITDA Margin (TTM)

CVM0.0%

QNCX0.0%

Net Margin (TTM)

CVM0.0%

QNCX0.0%

FCF Margin (TTM)

CVMN/A

QNCXN/A

Net Income (TTM)

CVM$-23M

QNCX$-92M

FCF (TTM)

CVM$-17M

QNCX$-47M

EPS (TTM)

CVM-$1.87

QNCX-$15.08

ROE (TTM)

CVM-20214.0%

QNCX-12702.0%

ROA (TTM)

CVM-10078.0%

QNCX-10448.0%

ROIC (TTM)

CVM-12370.0%

QNCX-11143.0%

Cash

CVM$7M

QNCX$116M

Debt

CVM$6M

QNCX$0

Net Cash/Debt

CVM$256K

QNCX$116M

Current Ratio (TTM)

CVM1.48x

QNCX14.52x

Quick Ratio (TTM)

CVM1.29x

QNCX14.28x

Debt/Equity (TTM)

CVM0.57x

QNCX0.48x

Debt/Assets (TTM)

CVM0.0%

QNCX0.0%

Interest Coverage (TTM)

CVMN/A

QNCXN/A

Net Debt/EBITDA (TTM)

CVM0.00x

QNCX0.00x

Beta

CVM0.62

QNCX1.80

52W Performance

CVM-80.7%

QNCX-91.7%

YTD Performance

CVM-62.3%

QNCX-94.7%

% from 52W High

CVM-81.3%

QNCX-96.5%

% from 52W Low

CVM118.0%

QNCX110.1%

Asset Turnover (TTM)

CVM0.01x

QNCX0.00x

FCF Yield (TTM)

CVM-49.4%

QNCX-151.2%

Earnings Yield (TTM)

CVM-67.0%

QNCX-297.4%

Dividend Yield (TTM)

CVMN/A

QNCXN/A

Rule of 40

CVM0.0

QNCX0.0

EV/GP/RG

CVMN/A

QNCXN/A

Ticker research

View CVM research View QNCX research

Metric	CVM CEL-SCI Corp	QNCX Quince Therapeutics Inc
Market & Valuation
Market Cap	$34M	$31M
Enterprise Value	$34M	$-85M
Price	$1.94	$31.73
P/E Ratio	N/A	N/A
P/S Ratio	72.73x	0.00x
EV/Sales	72.27x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.71x	0.27x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.01x	1.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	114.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-23M	$-92M
FCF (TTM)	$-17M	$-47M
EPS (TTM)	-$1.87	-$15.08
ROE (TTM)	-20214.0%	-12702.0%
ROA (TTM)	-10078.0%	-10448.0%
ROIC (TTM)	-12370.0%	-11143.0%
Financial Health
Cash	$7M	$116M
Debt	$6M	$0
Net Cash/Debt	$256K	$116M
Current Ratio (TTM)	1.48x	14.52x
Quick Ratio (TTM)	1.29x	14.28x
Debt/Equity (TTM)	0.57x	0.48x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	1.80
52W Performance	-80.7%	-91.7%
YTD Performance	-62.3%	-94.7%
% from 52W High	-81.3%	-96.5%
% from 52W Low	118.0%	110.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-49.4%	-151.2%
Earnings Yield (TTM)	-67.0%	-297.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CVM research	View QNCX research

Valuation

P/S Ratio

QNCX

0.00x

CVM

72.73x

EV/FCF

CVM

-2.01x

QNCX

1.81x

Growth & revenue

Forward Revenue Growth

QNCX

114.8%

CVM

0.0%

Profitability & performance

Gross Margin

CVM

0.0%

QNCX

0.0%

ROE

QNCX

-12702.0%

CVM

-20214.0%

FCF Yield %

CVM

-49.4%

QNCX

-151.2%

52-Week Performance

CVM

-80.7%

QNCX

-91.7%

Detailed metrics comparison

CVM

CEL-SCI Corp

QNCX

Quince Therapeutics Inc

Market Cap

CVM$34M

QNCX$31M

Enterprise Value

CVM$34M

QNCX$-85M

Price

CVM$1.94

QNCX$31.73

P/E Ratio

CVMN/A

QNCXN/A

P/S Ratio

CVM72.73x

QNCX0.00x

EV/Sales

CVM72.27x

QNCX0.00x

EV/EBITDA

CVM0.00x

QNCX0.00x

P/B Ratio

CVM3.71x

QNCX0.27x

P/FCF Ratio

CVMN/A

QNCXN/A

EV/FCF

CVM-2.01x

QNCX1.81x

PEG Ratio

CVMN/A

QNCXN/A

Forward P/E (NTM)

CVMN/A

QNCXN/A

Forward P/S (NTM)

CVMN/A

QNCXN/A

Revenue (TTM)

CVM$0

QNCX$0

Revenue Growth (YoY)

CVMN/A

QNCXN/A

Forward Rev Growth

CVM0.0%

QNCX114.8%

Gross Margin (TTM)

CVM0.0%

QNCX0.0%

Operating Margin (TTM)

CVM0.0%

QNCX0.0%

EBITDA Margin (TTM)

CVM0.0%

QNCX0.0%

Net Margin (TTM)

CVM0.0%

QNCX0.0%

FCF Margin (TTM)

CVMN/A

QNCXN/A

Net Income (TTM)

CVM$-23M

QNCX$-92M

FCF (TTM)

CVM$-17M

QNCX$-47M

EPS (TTM)

CVM-$1.87

QNCX-$15.08

ROE (TTM)

CVM-20214.0%

QNCX-12702.0%

ROA (TTM)

CVM-10078.0%

QNCX-10448.0%

ROIC (TTM)

CVM-12370.0%

QNCX-11143.0%

Cash

CVM$7M

QNCX$116M

Debt

CVM$6M

QNCX$0

Net Cash/Debt

CVM$256K

QNCX$116M

Current Ratio (TTM)

CVM1.48x

QNCX14.52x

Quick Ratio (TTM)

CVM1.29x

QNCX14.28x

Debt/Equity (TTM)

CVM0.57x

QNCX0.48x

Debt/Assets (TTM)

CVM0.0%

QNCX0.0%

Interest Coverage (TTM)

CVMN/A

QNCXN/A

Net Debt/EBITDA (TTM)

CVM0.00x

QNCX0.00x

Beta

CVM0.62

QNCX1.80

52W Performance

CVM-80.7%

QNCX-91.7%

YTD Performance

CVM-62.3%

QNCX-94.7%

% from 52W High

CVM-81.3%

QNCX-96.5%

% from 52W Low

CVM118.0%

QNCX110.1%

Asset Turnover (TTM)

CVM0.01x

QNCX0.00x

FCF Yield (TTM)

CVM-49.4%

QNCX-151.2%

Earnings Yield (TTM)

CVM-67.0%

QNCX-297.4%

Dividend Yield (TTM)

CVMN/A

QNCXN/A

Rule of 40

CVM0.0

QNCX0.0

EV/GP/RG

CVMN/A

QNCXN/A

Ticker research

View CVM research View QNCX research

Metric	CVM CEL-SCI Corp	QNCX Quince Therapeutics Inc
Market & Valuation
Market Cap	$34M	$31M
Enterprise Value	$34M	$-85M
Price	$1.94	$31.73
P/E Ratio	N/A	N/A
P/S Ratio	72.73x	0.00x
EV/Sales	72.27x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	3.71x	0.27x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.01x	1.81x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	114.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-23M	$-92M
FCF (TTM)	$-17M	$-47M
EPS (TTM)	-$1.87	-$15.08
ROE (TTM)	-20214.0%	-12702.0%
ROA (TTM)	-10078.0%	-10448.0%
ROIC (TTM)	-12370.0%	-11143.0%
Financial Health
Cash	$7M	$116M
Debt	$6M	$0
Net Cash/Debt	$256K	$116M
Current Ratio (TTM)	1.48x	14.52x
Quick Ratio (TTM)	1.29x	14.28x
Debt/Equity (TTM)	0.57x	0.48x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	1.80
52W Performance	-80.7%	-91.7%
YTD Performance	-62.3%	-94.7%
% from 52W High	-81.3%	-96.5%
% from 52W Low	118.0%	110.1%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-49.4%	-151.2%
Earnings Yield (TTM)	-67.0%	-297.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CVM research	View QNCX research